2024-10-19 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical devices, and consumer packaged goods conglomerate. 

**1. Performance Comparison:**

* **Cumulative Returns:** JNJ has yielded a cumulative return of 37.8%, lagging behind the S&P 500 (VOO) which has generated 137.88% over the same period. 
* **Relative Performance:** JNJ's performance has been significantly weaker than the S&P 500, with a relative performance of -100.08, meaning it has underperformed by 100.08% compared to the index. 
* **Relative Divergence:** JNJ's relative divergence sits at 4.75%, suggesting its performance is in the lower percentile compared to its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $165.12
* **5-Day Moving Average:** $163.91
* **20-Day Moving Average:** $161.89
* **60-Day Moving Average:** $162.46

JNJ is trading slightly above its short-term moving averages (5-day and 20-day), suggesting a potential short-term bullish sentiment. However, it remains below the 60-day moving average, indicating a potentially neutral to slightly bearish sentiment in the medium term.

**3. Technical Indicators:**

* **RSI:** 68.09 -  JNJ's RSI is approaching overbought territory, suggesting potential short-term weakness. 
* **PPO:** 0.29 - A positive PPO value indicates a bullish momentum, but the relatively low value suggests a neutral to moderately bullish momentum.
* **Delta_Previous_Relative_Divergence:** -3.92 -  The negative value indicates a recent short-term decline in relative performance compared to the market.
* **Expected Return:** 0.0% - JNJ is expected to provide a neutral return compared to the S&P 500 in the long term (2 years or more).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ has shown consistent revenue growth and a relatively stable EPS over the past quarters. The most recent earnings report (2024-07-25) revealed an EPS of 1.95, beating analysts' estimates. This positive earnings surprise could provide a boost to JNJ's stock price in the short term. However, the company faces challenges in the pharmaceutical sector, including increased competition and potential regulatory hurdles.

**5. News and Recent Issues:**

* **Recent Market Outlook:** According to Finbold, JNJ's stock price is projected to reach $180 by the end of 2024. 
* **Analyst Opinions:** Most analysts maintain a "Buy" or "Hold" rating on JNJ. However, some concerns remain regarding the company's exposure to litigation and potential regulatory pressures.
* **Performance Highlights:** JNJ is facing challenges in the pharmaceutical sector due to intense competition and rising litigation costs. However, its diversified portfolio and strong brand recognition continue to provide resilience. 

**6. Summary:**

JNJ's stock performance has lagged behind the S&P 500 in recent years. While the company has shown consistent earnings and revenue growth, its future performance remains uncertain due to competitive pressures and legal challenges. The current technical indicators suggest a potential short-term bullish sentiment, but the long-term outlook remains neutral. Investors considering JNJ should carefully assess the risks and opportunities associated with its business model and industry environment.

**7.  Recommendations:**

* **Short-term:**  Given the positive recent earnings surprise and the short-term technical indicators, JNJ could experience a short-term price appreciation. 
* **Long-term:**  JNJ's long-term outlook is less clear, and investors should carefully consider the risks before making a long-term investment.  
* **Overall:** JNJ offers a potential short-term upside, but its long-term growth potential remains uncertain. Investors should carefully weigh the risks and rewards before making any investment decisions. 
